The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth

A Kutikov, RG Uzzo - The Journal of urology, 2009 - auajournals.org
Purpose : Treatment decisions for renal malignancies depend largely on qualitative data,
including a description of tumor anatomy and the experience of the treating surgeon. Currently …

Guideline for management of the clinical T1 renal mass

…, RJ Leveillee, SF Matin, P Russo, RG Uzzo - The Journal of …, 2009 - auajournals.org
DETECTION of clinical stage 1 (7.0 cm) renal masses has increased in frequency and is
now a common clinical scenario for the practicing urologist. 1–4 These tumors are very …

Nephron sparing surgery for renal tumors: indications, techniques and outcomes

RG Uzzo, AC Novick - The Journal of urology, 2001 - auajournals.org
Purpose : A contemporary review of the indications, techniques and outcomes is presented
for nephron sparing approaches to solid renal masses, emphasizing their role for the …

Renal mass and localized renal cancer: AUA guideline

S Campbell, RG Uzzo, ME Allaf, EB Bass… - The Journal of …, 2017 - auajournals.org
Purpose : This AUA Guideline focuses on evaluation/counseling and management of adult
patients with clinically localized renal masses suspicious for cancer, including solid-…

The natural history of observed enhancing renal masses: meta-analysis and review of the world literature

…, RE Greenberg, DYT Chen, RG Uzzo - The Journal of …, 2006 - auajournals.org
Purpose : Standard therapy for an enhancing renal mass is surgical. However, operative
treatment may not be plausible in all clinical circumstances. Data on the natural history of …

A war on two fronts: cancer care in the time of COVID-19

…, MJ Edelman, EM Horwitz, RG Uzzo… - Annals of internal …, 2020 - acpjournals.org
As the COVID-19 pandemic accelerates in the United States, this commentary asks how
oncology specialists and allied providers are balancing a delay in cancer diagnosis or treatment …

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood… - The Lancet, 2016 - thelancet.com
Background Renal-cell carcinoma is highly vascular, and proliferates primarily through
dysregulation of the vascular endothelial growth factor (VEGF) pathway. We tested sunitinib and …

Why summary comorbidity measures such as the Charlson comorbidity index and Elixhauser score work

SR Austin, YN Wong, RG Uzzo, JR Beck… - Medical care, 2015 - journals.lww.com
Background: Comorbidity adjustment is an important component of health services research
and clinical prognosis. When adjusting for comorbidities in statistical models, researchers …

Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I

…, SS Chang, JA Karam, L Souter, RG Uzzo - The Journal of …, 2021 - auajournals.org
Purpose: This AUA Guideline focuses on evaluation/counseling/management of adult
patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing …

Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review

DA Kunkle, BL Egleston, RG Uzzo - The Journal of urology, 2008 - auajournals.org
Purpose : The incidence of renal cell carcinoma is increasing due to the incidental detection
of small renal masses. Resection, predominantly by nephron sparing surgery, remains the …